Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
BMC Pulm Med
2021 Jun 06;211:190. doi: 10.1186/s12890-021-01553-z.
Show Gene links
Show Anatomy links
EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation.
Li Y
,
Li Y
,
Zhang H
,
Shi R
,
Zhang Z
,
Liu H
,
Chen J
.
???displayArticle.abstract???
BACKGROUND: The echinoderm microtubule-associated protein-like-4 anaplastic lymphoma kinase (EML4-ALK) fusion gene was identified in a subset of non-small cell lung cancer (NSCLC) patients. They responded positively to ALK inhibitors. This study aimed to characterize the mechanisms triggered by EML4-ALK to induce NSCLC transformation.
METHODS: HEK293 and NIH3T3 cells were transfected with EML4-ALK variant 3 or pcDNA3.1-NC. H2228 cells were transfected with siRNA-EML4-ALK or siRNA-NC. Cell viability and proliferation were measured by the CCK-8 and EdU methods, respectively. Flow cytometry revealed apoptosis. Gene expression profiles were generated from a signaling pathway screen in EML4-ALK-regulated lung cancer cells and verified by qPCR and Western blotting. The co-immunoprecipitation and immunohistochemistry/ immunofluorescence determined the interaction and colocalization of JAK2-STAT pathway components with EML4-ALK.
RESULTS: Microarray identified several genes involved in the JAK2-STAT pathway. JAK2 and STAT6 were constitutively phosphorylated in H2228 cells. EML4-ALK silencing downregulated phosphorylation of STAT6. Expression of EML4-ALK in HEK293 and NIH3T3 cells activated JAK2, STAT1, STAT3, STAT5, and STAT6. In EML4-ALK-transfected HEK293 cells and EML4-ALK-positive H2228 cells, activated STAT6 and JAK2 colocalized with ALK. STAT3 and STAT6 were phosphorylated and translocated to the nucleus of H2228 cells following IL4 or IL6 treatment. Apoptosis increased, while cell proliferation and DNA replication decreased in H2228 cells following EML4-ALK knockdown. In contrast, HEK293 cell viability increased following EML4-ALK overexpression, while H2228 cell viability significantly decreased after treatment with ALK or JAK-STAT pathway inhibitors.
CONCLUSIONS: Our data suggest that the aberrant expression of EML4-ALK leads to JAK2-STAT signaling pathway activation, which is essential for the development of non-small cell lung cancer.
???displayArticle.pubmedLink???
34090412
???displayArticle.pmcLink???PMC8180148 ???displayArticle.link???BMC Pulm Med ???displayArticle.grants???[+]
81773207 National Natural Science Foundation of China, 82072595 National Natural Science Foundation of China, 17YFZCSY00840 Natural Science Foundation of Tianjin City, 19YFZCSY00040 Natural Science Foundation of Tianjin City, 18PTZWHZ00240 Natural Science Foundation of Tianjin City, 19JCYBJC27000 Natural Science Foundation of Tianjin City, TJTZJH-GCCCXCYTD-2-6 High Tech Leader & Team of Tianjin city, LX202002 Shihezi University Oasis Scholars Research Startup Project
Fig. 1. Microarray analysis of H2228 cells without or with EML4-ALK knockdown and of HEK293 cells expressing or not the EML4-ALK variant 3. a The heat map shows the regulation of a number of JAK2-STAT pathway genes. b Expression of JAK2-STAT pathway-related genes measured by real-time PCR
Fig. 2. Activation status of STAT proteins in EML4-ALK-positive lung cancer. a STAT6 and JAK2 were constitutively phosphorylated in H2228 cells. EML4-ALK knockdown downregulated phosphorylation of JAK2 and STAT6 in H2228 cells. b colocalization of ALK, p-STAT6, and p-JAK2 staining in primary tumor tissue. c Representative images of ALK,p-JAK2 and p-STAT6 expression by immunohistochemical analysis in the primary tumors and metastatic tumors of EML4-ALK-positive lung cancer patients
Fig. 3. EML4-ALK transfection activated JAK2, STAT1, STAT3, STAT5, and STAT6 in HEK293 and NIH3T3 cells
Fig. 4. Interactions between components of the JAK2-STAT pathway and EML4-ALK. a Active STAT6 and JAK2 colocalized with ALK in EML4-ALK-transfected HEK293 cells and in H2228 cells. b: ALK and phosphorylated STAT6 protein were co-immunoprecipitated with JAK2 in EML4-ALK-transfected HEK293 cells
Fig. 5. IL4 and IL6 affected the JAK2-STAT pathway in EML4-ALK-positive cells. a STAT3 and STAT6 were phosphorylated and translocated to the nuclei of H2228 cells following IL4 or IL6 treatment. b Microarray analysis of H2228 cells stimulated or not with IL4. The heat map identifies modified proteins associated with the JAK2-STAT pathway, the regulation of the actin cytoskeleton, the cell cycle, cell adhesion, and the positive regulation of cell proliferation
Fig. 6. Effect of oncogenic EML4-ALK tyrosine kinase on the biological behaviors of lung cancer cells. a EML4-ALK levels in transfected H2228 and HEK293 cells. b Increased apoptosis in H2228 cells following EML4-ALK knockdown measured by flow cytometry. c Cell viability, measured by the CCK8 assay, was increased by EML4-ALK expression in HEK293 cells. d–e Viability and proliferation of H2228 cells decreased after knockdown of EML4-ALK or STAT6. f H2228 cell viability following treatment with ALK or JAK-STAT pathway inhibitors as measured by the CCK-8 assay. *P < 0.05
Ahonen,
Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells.
2003, Pubmed
Ahonen,
Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells.
2003,
Pubmed
Chen,
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
2010,
Pubmed
Das,
Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
2007,
Pubmed
Garcia,
Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells.
1997,
Pubmed
Hodge,
Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom's macroglobulinemia.
2014,
Pubmed
Huang,
STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo.
2011,
Pubmed
Ivanov,
Cooperation between STAT3 and c-jun suppresses Fas transcription.
2001,
Pubmed
Jemal,
Cancer statistics, 2008.
2008,
Pubmed
Kiu,
Biology and significance of the JAK/STAT signalling pathways.
2012,
Pubmed
Koivunen,
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
2008,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Lee,
Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.
2017,
Pubmed
Leung,
Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer.
2012,
Pubmed
Li,
Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.
2013,
Pubmed
McFarland,
Therapeutic potential of AZD1480 for the treatment of human glioblastoma.
2011,
Pubmed
Mitsudomi,
Biological and clinical implications of EGFR mutations in lung cancer.
2006,
Pubmed
Normant,
The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
2011,
Pubmed
,
Echinobase
Pencik,
JAK-STAT signaling in cancer: From cytokines to non-coding genome.
2016,
Pubmed
Rikova,
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
2007,
Pubmed
Ritz,
Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.
2009,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Soda,
A mouse model for EML4-ALK-positive lung cancer.
2008,
Pubmed
Takeuchi,
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
2008,
Pubmed
Takeuchi,
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.
2009,
Pubmed
Talati,
Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.
2015,
Pubmed
Wang,
Targeted blockage of signal transducer and activator of transcription 5 signaling pathway with decoy oligodeoxynucleotides suppresses leukemic K562 cell growth.
2011,
Pubmed
Wei,
Stat6 cooperates with Sp1 in controlling breast cancer cell proliferation by modulating the expression of p21(Cip1/WAF1) and p27 (Kip1).
2013,
Pubmed
Wong,
The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
2009,
Pubmed
,
Echinobase
Zahn,
A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.
2017,
Pubmed
